Adropin to protect the brain after a subarachnoid hemorrhage
Neurovascular protection by adropin in acute neural injury from subarachnoid hemorrhage
See whether a natural peptide called adropin can protect the brain and blood vessels in people who have had a subarachnoid hemorrhage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11144279 on NIH RePORTER |
What this research studies
Researchers are exploring whether boosting adropin can reduce brain cell damage and blood vessel problems that follow bleeding around the brain (subarachnoid hemorrhage). They will use laboratory models that mimic SAH to measure blood flow, vessel function, oxidative stress, and tissue injury while testing how adropin affects nitric oxide signaling and endothelial leakiness. The team may also analyze human samples or biomarkers to connect the lab findings to people who survive SAH. The aim is to point toward treatments that lower the risk of delayed brain infarction and long-term cognitive problems after SAH.
Who could benefit from this research
Good fit: People who recently survived a subarachnoid hemorrhage and are at risk for delayed cerebral infarction would be the most relevant group for future related trials.
Not a fit: People without subarachnoid hemorrhage or those with other types of brain injury are unlikely to receive direct benefit from this specific project.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that reduce brain injury and improve recovery after subarachnoid hemorrhage.
How similar studies have performed: Preclinical animal and cell studies show adropin influences eNOS activity and reduces endothelial damage, but clinical benefit in SAH patients has not yet been demonstrated.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Hoh, Brian Lim — University of Florida
- Study coordinator: Hoh, Brian Lim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.